BJERKHOLT ERIC 4

What Happened Eric Bjerkholt, Chief Financial Officer of Mirum Pharmaceuticals (MIRM), was granted a total of 49,900 derivative awards on January 28, 2026: 18,140 units @ $0.00, 11,760 units @ $0.00, and 20,000 units @ $0.00. These are restricted stock units (RSUs) and performance RSUs (PSUs) — i.e., contingent rights to receive Mirum common shares when the awards vest. No cash was paid for these awards; they are compensation grants, not open-market purchases.

Key Details

• Transaction date: January 28, 2026; Form 4 filed January 30, 2026 (timely filing).
• Grants: 18,140 RSUs (acq. $0.00), 11,760 RSUs (acq. $0.00), 20,000 PSUs (acq. $0.00) — total 49,900 awards.
• Vesting summaries (from footnotes):
  • 18,140: 25% vests one year after Jan 28, 2026; remaining balance vests in 36 equal monthly installments thereafter.
  • 11,760: RSUs (each equals one share) with 1/3 vesting on each anniversary of Jan 28, 2026 (fully vested after 3 years).
  • 20,000 PSUs: performance criteria were met on Jan 28, 2026; 2/3 of these shares vest on March 15, 2026 and the remaining 1/3 vests on March 15, 2027.
• Shares owned after the transaction: Not specified in the filing.
• Transaction code: A = Award/Grant; these are derivative awards (RSUs/PSUs). No 10b5-1, tax withholding, or sale noted in the filing.

Context RSUs and PSUs are compensation awards that convert into common shares only when vesting conditions (time and/or performance) are met; awards reported at $0 acquisition price are typical for such grants. Because these are grants (not open-market purchases or sales), they reflect compensation rather than an immediate buy/sell signal. The PSU performance condition was confirmed on Jan 28, 2026, which triggered the stated future vesting dates.